Abstract

Objectives: Conduits for reconstructing right ventricular outflow tract (RVOT) in children with congenital heart disease have evolved for better durability over the past decades, but conduits failure remains common. We designed decellularized and photooxidatively crosslinked bovine jugular vein conduit (DP-BJVC) and now aim to evaluate the midterm results of DP-BJVC for RVOT reconstruction.Methods: Ninety patients (median age: 4.2 years) undergoing RVOT reconstruction using DP-BJVC were prospectively followed for median of 4.7 years (range: 0.2–16.1 years). Kaplan–Meier analysis was used to examine the survival, freedom from conduit explantation and catheter-based reintervention. Risk factors were analyzed with Cox regression analysis.Results: Follow-up was completed in 92% of patients. There were five (5.6%) early deaths. The 10-year survival rate was 85.2%, with palliative procedure at DP-BJVC implantation as the risk factor. The 10-year freedom from conduit explantation and reintervention were 84.4 and 67.3% respectively, with previous cardiac operation as the only risk factor for explantation. Complications during the follow-up included conduit stenosis (peak gradient ≥50 mmHg) in 12 (12.9%), severe regurgitation in 2 (2.4%), and infective endocarditis in 2 (2.4%). The annual increase in gradient was highest in the first year (P = 0.003), but not appreciably afterwards. The echo-measured annulus diameter trends to increase by an average of 0.37 mm per year. Calcification appeared mild in the failed conduits.Conclusions: DP-BJVC provides satisfactory durability and functionality for RVOT reconstruction for children, with low morbidity of stenosis and endocarditis, as well as increase in diameter mildly with age in midterm follow-ups.

Highlights

  • The surgical reconstruction of right ventricular outflow tract (RVOT) with valved conduit remains a common cardiac procedure for patients with congenital heart diseases (CHD)(1)

  • Conduits for reconstructing right ventricular outflow tract (RVOT) in children with congenital heart disease have evolved for better durability over the past decades, but conduits failure remains common

  • Ninety patients undergoing RVOT reconstruction using DP-bovine jugular vein conduit (BJVC) were prospectively followed for median of 4.7 years

Read more

Summary

Introduction

The surgical reconstruction of right ventricular outflow tract (RVOT) with valved conduit remains a common cardiac procedure for patients with congenital heart diseases (CHD)(1). The Contegra conduit (Medtronic Inc., Minneapolis, Minnesota, USA), a glutaraldehyde-treated bovine jugular vein conduit (BJVC) developed in 1990s, is one of the most successful alternates. It makes up the shortage of homograft and costs less. The graft-related immune response induced by residual donor cells and cell debris plays an important role in the failure of glutaraldehyde-treated xenografts [11]. The latter factor may be avoided by decellularization, which has been adopted in cardiovascular biomaterials over 30 years [12]. Its application was limited largely within Japan by the inconsistent quality control of hand-sewn valve until recent years

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call